Graft-Vs-Host Disease

>

Latest News

FDA Approves Axatilimab for Chronic Graft-vs-Host Disease
FDA Approves Axatilimab for Chronic Graft-vs-Host Disease

August 14th 2024

The FDA approved axatilimab for adults and children with chronic graft-vs-host disease whose disease progressed after 2 or more lines of systemic therapy.

BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD
BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

August 11th 2024

Matched and Mismatched Unrelated Donors May Confer Similar Survival Rates for HCT
Matched and Mismatched Unrelated Donors May Confer Similar Survival Rates for HCT

July 30th 2024

Responses to Belumosudil Persist at 3 Years in Chronic GVHD
Responses to Belumosudil Persist at 3 Years in Chronic GVHD

May 7th 2024

Patient-Reported Symptoms via Mobile App May Help Expedite GVHD Identification, Treatment
Patient-Reported Symptoms via Mobile App May Help Expedite GVHD Identification, Treatment

April 26th 2024

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.